We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Indian Diagnostic Company Transasia Bio-Medical Acquires Pliva Lachema Diagnostica

By LabMedica International staff writers
Posted on 20 Oct 2009
An Indian clinical diagnostics company, Transasia Bio-Medicals Ltd. More...
(Mumbai, India) has acquired Pliva Lachema Diagnostika (Brno, Czech Republic). The acquisition will bring advanced technology within reach for India's vast population.

The acquisition provides an opportunity for Transasia and ERBA to introduce newer products to the swiftly developing markets of Asia. Transasia and its 100% German subsidiary, ERBA Diagnostics Mannheim GmbH (Germany) have a team of experienced marketing and service professionals and a large distribution network. It markets products in countries, which include Italy, Germany, France, China, Turkey, Russia, and around the globe.

PLIVA Lachema Diagnostika develops, produces, and markets in vitro diagnostics (IVD) products for urine analysis, biochemistry, and microbiology. The company has an extensive marketing and distribution network in the countries of Central and Eastern Europe, which will complement the current market potential and product lines of Transasia and ERBA Mannheim

Lachema's customers in Central and Eastern Europe will have access to Transasia's large product range in clinical chemistry, immunoturbidimetry, and immunology. Transasia Bio-Medicals Ltd. and ERBA Diagnostics Mannheim intend to invest more than US$1 million in Lachema to increase its manufacturing capacities and add new quality, affordable, wide spectrum products in the near future.

Related Links:
Transasia Bio-Medicals Ltd.
Pliva Lachema Diagnostika



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
POC Immunoassay Analyzer
Procise DX
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.